Beam Therapeutics Inc. (BEAM) Income Statement Analysis

See more : Cyfrowy Polsat S.A. (CPS.WA) Income Statement Analysis – Financial Results

Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Beam Therapeutics Inc. (BEAM)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.beamtx.com

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017
Revenue	377.71M	60.92M	51.84M	24.00K	18.00K	0.00	0.00
Cost of Revenue	437.38M	22.58M	16.44M	103.18M	5.41M	650.00K	11.00K
Gross Profit	-59.67M	38.34M	35.40M	-103.16M	-5.39M	-650.00K	-11.00K
Gross Profit Ratio	-15.80%	62.94%	68.29%	-429,812.50%	-29,938.89%	0.00%	0.00%
Research & Development	437.38M	311.59M	387.09M	103.18M	54.62M	33.87M	5.86M
General & Administrative	116.81M	87.81M	57.22M	29.61M	20.55M	11.87M	2.02M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	116.81M	87.81M	57.22M	29.61M	20.55M	11.87M	2.02M
Other Expenses	0.00	0.00	0.00	0.00	-71.00K	-10.04M	378.00K
Operating Expenses	554.19M	399.40M	444.31M	132.78M	75.17M	45.74M	7.88M
Cost & Expenses	554.19M	399.40M	444.31M	132.78M	75.17M	45.74M	7.88M
Interest Income	0.00	15.30M	9.00K	1.57M	2.49M	292.00K	0.00
Interest Expense	0.00	15.30M	9.00K	1.57M	187.00K	0.00	0.00
Depreciation & Amortization	20.01M	22.58M	16.44M	9.47M	5.41M	650.00K	11.00K
EBITDA	-156.47M	-324.33M	-392.47M	-128.03M	-71.65M	-45.09M	-7.99M
EBITDA Ratio	-41.43%	-659.03%	-799.13%	-269,270.83%	-384,644.44%	0.00%	0.00%
Operating Income	-176.49M	-338.48M	-392.47M	-132.76M	-75.15M	-45.74M	-7.88M
Operating Income Ratio	-46.73%	-555.61%	-757.01%	-553,166.67%	-417,522.22%	0.00%	0.00%
Total Other Income/Expenses	45.32M	78.30M	21.83M	-61.83M	-3.17M	-71.00M	-122.00K
Income Before Tax	-131.16M	-260.18M	-370.64M	-194.59M	-78.33M	-116.74M	-8.00M
Income Before Tax Ratio	-34.73%	-427.08%	-714.91%	-810,800.00%	-435,144.44%	0.00%	0.00%
Income Tax Expense	1.37M	3.41M	-29.28M	61.83M	116.00K	-71.00M	500.00K
Net Income	-132.53M	-263.59M	-341.36M	-256.42M	-78.44M	-115.26M	-8.00M
Net Income Ratio	-35.09%	-432.68%	-658.44%	-1,068,433.33%	-435,788.89%	0.00%	0.00%
EPS	-1.72	-3.76	-5.31	-5.49	-1.53	-3.28	-0.62
EPS Diluted	-1.72	-3.76	-5.31	-5.49	-1.53	-3.28	-0.62
Weighted Avg Shares Out	77.15M	70.02M	64.23M	46.73M	51.34M	35.14M	12.95M
Weighted Avg Shares Out (Dil)	77.15M	70.02M	64.23M	46.73M	51.34M	35.14M	12.95M

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

September 5, 2024zacks.com

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?

3 Gene Editing Stocks with Potential to Transform Medicine

August 9, 2024investorplace.com

Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation.

Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss

August 7, 2024zacks.com

Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2024zacks.com

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago.

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

August 6, 2024globenewswire.com

U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa)

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

July 26, 2024zacks.com

Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

July 24, 2024investorplace.com

Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in precision genetic medicines, which is a growing and viable market.

3 Gene Editing Stocks Shaping the Future of Medicine

July 22, 2024investorplace.com

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.